Last reviewed · How we verify
PF03446962
At a glance
| Generic name | PF03446962 |
|---|---|
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma (PHASE2)
- A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma (PHASE2)
- PF-03446962 in Relapsed or Refractory Urothelial Cancer (PHASE2)
- Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer (PHASE1)
- A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer (PHASE2)
- Asian Phase I Study Of PF-03446962 (PHASE1)
- A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF03446962 CI brief — competitive landscape report
- PF03446962 updates RSS · CI watch RSS
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano portfolio CI